China Drug Makers Brace As Anti-Graft Campaign Impact Surfaces
Simcere, Hengrui, and Zai Lab are among the first Chinese pharma firms to report various forms of impact from the gathering storm of a national anti-corruption campaign launched in July in the healthcare and pharma sectors.
You may also be interested in...
Join the Pink Sheet's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.
Join Scrip's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.
As Beijing gets tougher in an all-out campaign to root out corruption and non-compliance in the pharma sector, more physician conferences are jeopardized and an increasing number of hospital presidents are placed under investigation. Meanwhile, one industry association issues new guidance for members.